Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center

Journal of Allergy and Clinical Immunology

Volumn 131, Issue 2, 2013, Pages

  Ducruet, Thierry ^a   Levasseur, Marie Claude ^a   Des Roches, Anne ^a   Kafal, Ayman ^b   Dicaire, Renée ^a   Haddad, Elie ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CSL Behring   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE DEFICIENCY; LETTER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS;

EID: 84873405539     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2012.08.022     Document Type: Article

References (12)

1. H.M. Chapel, G.P. Spickett, D. Ericson, W. Engl, M.M. Eibl, and J. Bjorkander The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy J Clin Immunol 20 2000 94 100
2. A. Gardulf, U. Nicolay, O. Asensio, E. Bernatowska, A. Bock, and B.C. Carvalho Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies-a prospective, multi-national study J Clin Immunol 26 2006 177 185
3. H.D. Ochs, S. Gupta, P. Kiessling, U. Nicolay, and M. Berger Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases J Clin Immunol 26 2006 265 273
4. J. Beaute, P. Levy, V. Millet, M. Debre, Y. Dudoit, and L. Le Mignot Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies Clin Exp Immunol 160 2010 240 245
5. A. Gardulf, V. Andersen, J. Bjorkander, D. Ericson, S.S. Froland, and R. Gustafson Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs Lancet 345 1995 365 369
6. B. Hogy, H.O. Keinecke, and M. Borte Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance Eur J Health Econ 6 2005 24 29
7. S.K. Membe, C. Ho, K. Cimon, A. Morrison, A. Kanani, and C.M. Roifman Economic assessment of different modalities of immunoglobulin replacement therapy Immunol Allergy Clin North Am 28 2008 861 874 x
8. L.D. Notarangelo, A. Fischer, R.S. Geha, J.L. Casanova, H. Chapel, and M.E. Conley Primary immunodeficiencies: 2009 update J Allergy Clin Immunol 124 2009 1161 1178
9. A. Gardulf, U. Nicolay, D. Math, O. Asensio, E. Bernatowska, and A. Bock Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home J Allergy Clin Immunol 114 2004 936 942
10. U. Nicolay, P. Kiessling, M. Berger, S. Gupta, L. Yel, and C.M. Roifman Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home J Clin Immunol 26 2006 65 72
11. S. Jolles, E. Bernatowska, J. de Gracia, M. Borte, V. Cristea, and H.H. Peter Efficacy and safety of Hizentra((R)) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy Clin Immunol 141 2011 90 102
12. J.B. Hagan, M.B. Fasano, S. Spector, R.L. Wasserman, I. Melamed, and M.A. Rojavin Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency J Clin Immunol 30 2010 734 745